See more : Auction Technology Group plc (ATG.L) Income Statement Analysis – Financial Results
Complete financial analysis of Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zylox-Tonbridge Medical Technology Co., Ltd., a leading company in the Medical – Devices industry within the Healthcare sector.
- Global Acquisitions Corporation (AASP) Income Statement Analysis – Financial Results
- Senseonics Holdings, Inc. (SENS) Income Statement Analysis – Financial Results
- boohoo group plc (BHHOF) Income Statement Analysis – Financial Results
- Línea Directa Aseguradora, S.A. (LDA.MC) Income Statement Analysis – Financial Results
- Frencken Group Limited (E28.SI) Income Statement Analysis – Financial Results
Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK)
About Zylox-Tonbridge Medical Technology Co., Ltd.
Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices China and internationally. It primarily offers ThromBite Clot Retriever Device, which is intended to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke; Balloon Guiding Catheter; Cylone Aspiration Catheter; ZENFLEX Pro Peripheral Drug-eluting Stent System for complex lesions and restenotic symptomatic lesions; ZENFlex Peripheral Stent System to deliver a self-expanding stent to the iliac artery, superficial femoral arteries, and/or proximal popliteal arteries through a 6F delivery system; and drug-coated percutaneous transluminal angioplasty (PTA) Balloon Catheters that are indicated for PTA of stenosis or occlusion lesions in iliac, femoral, or popliteal arteries. The company also provides Ton-Bridge extra soft coils for the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities, such as arteriovenous malformations and arteriovenous fistulae; microcatheter for coiling; distal access catheter; glycine micro catheter for professional physician to selectively inject or input control medium and/or embolic materials, and/or appropriate devices; Intracranial PTA balloon catheter; vascular snare; and snare retrieval kit for IVC filter. Zylox-Tonbridge Medical Technology Co., Ltd. was incorporated in 2012 and is headquartered in Zhejiang, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 527.75M | 334.09M | 177.91M | 27.63M | 4.92M |
| Cost of Revenue | 142.77M | 81.42M | 46.03M | 11.34M | 3.73M |
| Gross Profit | 384.99M | 252.67M | 131.88M | 16.29M | 1.19M |
| Gross Profit Ratio | 72.95% | 75.63% | 74.13% | 58.94% | 24.24% |
| Research & Development | 261.01M | 233.46M | 168.10M | 72.07M | 53.03M |
| General & Administrative | 114.09M | 109.34M | 100.60M | 30.99M | 16.96M |
| Selling & Marketing | 163.83M | 140.14M | 95.27M | 20.45M | 6.76M |
| SG&A | 277.92M | 249.47M | 195.87M | 51.45M | 23.72M |
| Other Expenses | 2.58M | -8.08M | -14.03M | -9.44M | -6.61M |
| Operating Expenses | 541.51M | 474.86M | 349.94M | 114.07M | 70.14M |
| Cost & Expenses | 684.28M | 556.28M | 395.97M | 125.41M | 73.86M |
| Interest Income | 79.04M | 95.57M | 13.09M | 360.00K | 89.00K |
| Interest Expense | 1.25M | 722.00K | 307.00K | 666.00K | 1.04M |
| Depreciation & Amortization | 35.88M | 26.27M | 13.38M | 9.64M | 9.57M |
| EBITDA | -41.60M | -86.57M | -199.95M | -90.16M | -58.96M |
| EBITDA Ratio | -7.88% | -23.86% | -112.38% | -332.29% | -1,199.11% |
| Operating Income | -156.52M | -222.19M | -218.06M | -97.78M | -68.94M |
| Operating Income Ratio | -29.66% | -66.50% | -122.56% | -353.89% | -1,402.14% |
| Total Other Income/Expenses | 77.79M | 94.84M | 12.79M | -306.00K | -946.00K |
| Income Before Tax | -78.73M | -113.56M | -199.69M | -100.47M | -66.65M |
| Income Before Tax Ratio | -14.92% | -33.99% | -112.24% | -363.61% | -1,355.44% |
| Income Tax Expense | 0.00 | 6.85M | -13.64M | -986.00K | -1.89M |
| Net Income | -78.73M | -120.41M | -186.05M | -99.48M | -64.76M |
| Net Income Ratio | -14.92% | -36.04% | -104.57% | -360.04% | -1,317.08% |
| EPS | -0.24 | -0.36 | -0.63 | -0.31 | -0.20 |
| EPS Diluted | -0.24 | -0.36 | -0.63 | -0.31 | -0.20 |
| Weighted Avg Shares Out | 328.71M | 330.39M | 294.60M | 323.40M | 323.40M |
| Weighted Avg Shares Out (Dil) | 328.71M | 330.39M | 294.60M | 323.40M | 323.40M |
Source: https://incomestatements.info
Category: Stock Reports